REG - Beximco Pharmaceut - Statement re: media comment

Beximco PharmaceuticalsAnnouncement

25/08/2021 18:05

RNS Number : 8050J
  
Beximco Pharmaceuticals Ltd
  
25 August 2021
  
 

25 August 2021
 
BEXIMCO PHARMACEUTICALS LTD. 
 
Statement re: media comment  
 
Beximco Pharmaceuticals Limited ("Beximco Pharma" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, notes the recent media comment that export of Covid-19 vaccine doses from India could be delayed until 2022.
 
At this time, there is no further update to the Company's announcement on 7 July 2021 regarding its agreement with the Government of Bangladesh (GOB) and the Serum Institute of India Private Limited (SII) for the supply of Covid-19 vaccine doses in Bangladesh, and the Indian Government's controls on vaccine exports remain in place. The Company remains in dialogue with GOB and SII and a further announcement will be made as appropriate. 
 
For further information please visit www.beximcopharma.com or enquire to: 
 



Beximco Pharma




Nazmul Hassan MP, Managing Director
Tel: +880 2 58611001, ext.20080
 




S M Rabbur Reza, Chief Operating Officer 
Tel: +880 2 58611001, ext. 20111 
 
Mohammad Ali Nawaz, Chief Financial Officer
Tel: +880 2 58611001, ext.20030
 




SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0)20 3368 3551 / 3555
 




SP Angel Corporate Finance LLP (Broker)
Vadim Alexandre / Abigail Wayne
Tel: +44 (0) 20 3470 0470
 




FTI Consulting
Simon Conway / Victoria Foster Mitchell / Sam Purewal
Tel: +44 (0)20 3727 1000
 



 
About Beximco Pharmaceuticals Limited
Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.
 
Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 5,500 employees are driving the company towards achieving its aspiration to be among the most admired companies in the world.
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
MSCQELFLFVLXBBE